The authors directly visualized two human MYH11 tail variants expressed in vascular smooth muscle cells (VSMC) using live-cell approaches. One variant, K1256del, has been classified as pathogenic by prior genetic evidence. The other, A1839V, was reported as a variant of uncertain significance identified in a patient with severe aortoiliac aneurysmal disease. The study team observed filament behavior in real time to compare assembly, exchange dynamics, and responses to agonist-induced contraction. The source did not report animal or clinical intervention data; all results derive from cellular phenotyping experiments.
Data indicated both variants reduced assembly of smooth muscle myosin II (SMII) filaments, but with different severities and qualitative features. A1839V mostly preserved filamentous organization, with many filaments retaining elongated morphology across the imaging period. By contrast, K1256del markedly disrupted filament architecture: filaments appeared fragmented and network organization was altered. The investigators reported accelerated filament exchange kinetics in K1256del-expressing cells and increased overall SMII network flow compared with controls. The study team noted these behaviors as characteristic differences between an intermediate phenotype (A1839V) and a severe-disruption phenotype (K1256del).
Both variants reduced measurable VSMC contractile output in the authors' assays, although the degree of reduction varied. A1839V-expressing cells showed partial retention of contraction relative to wild-type controls. K1256del-expressing cells displayed a larger decrement in contractile function. The cohort also exhibited changes in adhesion machinery: K1256del cells had reduced focal adhesion organization, which the investigators linked to the observed loss of coordinated contractile behavior. The source did not provide quantitative traction force values, numeric effect sizes, or detailed statistical outputs in the abstract; those metrics were not reported in the text provided here.
The study team induced contraction pharmacologically and monitored filament responses. A1839V showed partial agonist-induced stabilization of SMII filaments, consistent with a retained—but impaired—capacity to respond to contractile stimuli. In contrast, K1256del abolished the filament stabilization response to induced contraction; filaments in those cells failed to show the expected reduction in turnover or structural consolidation following agonist treatment. These differential responses formed a central functional distinction between the two variants in live cells.
Investigators interpreted the loss of agonist-triggered filament stabilization as a cellular mechanism connecting MYH11 tail variation to impaired VSMC mechanics. The data indicated that when SMII filaments cannot stabilize during contraction, focal adhesion architecture and contractile output are compromised, producing the phenotypes observed with K1256del. For A1839V, partial stabilization and retained filament structure offered a plausible explanation for its intermediate cellular phenotype. The authors emphasized that direct live-cell phenotyping can discriminate variant-specific defects in the contractile apparatus and therefore serve as a functional readout to complement genetic classification.
The preprint specifies that these findings derive from live-cell imaging in cultured VSMCs and do not include in vivo validation; the authors recommended additional mechanistic and animal studies to connect cellular phenotypes to tissue- and organism-level disease. The source did not report clinical endpoints, patient treatment details, or therapeutic interventions, nor did it provide precise quantitative metrics in the abstract available here. Authors proposed that the phenotyping approach offers a scalable strategy to prioritize MYH11 variants for deeper mechanistic study and for subsequent in vivo work. Open questions that remain, as noted in the manuscript, include how these filament dynamics map onto aneurysm development in patients and which downstream signaling pathways mediate the link between filament instability and focal adhesion disruption.
Limitations documented by the authors offer concrete next steps: perform in vivo validation of variant effects, quantify biomechanical consequences in tissue models, and integrate functional phenotyping with genetic classification workflows to prioritize variants for translational study. The preprint declares no competing interests and lists NIH funding, but does not provide additional regulatory milestones or clinical translation timelines within the source text.